the considerable need for prevention-based approaches towards NMSC. Therefore, we have focused our studies on chemopreventive strategies which target the inflammation gatekeepers, GCs, to effectively diminish tumorigenesis.
The modulation of GCs at the pre-receptor level is both necessary for their proper function and essential for tissue-specific glucocorticoid requirements. While GCs are regulated by ligand and receptor concentrations in the plasma, an additional and vital level of pre-receptor modulation of these critical hormones is carried out by 11β-hydroxysteroid dehydrogenases (11βHSDS). 6 The function of these enzymes is of vital importance for localized activation and deactivation of GCs. 7 11βHSD1 and 11βHSD2 catalyze the interconversion of active GCs to their inactive counterparts such as the conversion of cortisol to cortisone by 11βHSD2 and, the reverse reaction whereby 11βHSD1 results in an active cortisol molecule. 8 Specifically, 11βHSD2 deactivates GCs by converting the hydroxyl group on the C-11 position to a ketone group, rendering it inactive; it does this in a tissue specific manner. 9, 10 Through the enzymatic action of 11βHSD2, the amount of active GC which is available to the receptor can be carefully modulated within the designated target tissue, thus creating an advantageous target for modulating GCs to combat tumorigenesis.
Significant evidence in the literature has shown that 11βHSD2 is expressed in many different cancer tissues, however, it is not expressed in the normal tissue counterparts. [11] [12] [13] Specific examples of this 11βHSD1/11βHSD2 expression "switch" as it is described in the literature include occurrences in breast cancer, colon cancer, prostate, endometrial, and ovarian cancer cell lines. 12, [14] [15] [16] [17] Given the fact that GCs play an important role in skin proliferation and inflammation, it was surprising to find that 11βHSD2 characterization in NMSC has not yet been carried out. Moreover, this critical GC modulating enzyme has also not yet been evaluated for its role in transformation in NMSC, and it has been hypothesized that preferential expression of 11βHSD2 may play a role in transformation of certain types of cancer. 13 Therefore, we propose that NMSC development and progression may be circumventing regulation of cellular proliferation by increasing expression of 11βHSD2 and thereby locally inactivating GCs. As the "switch" in 11βHSD1/11βHSD2 expression has been reported in various cancer types, much of the research on these enzymes as they relate to cancer has now turned towards elucidating and characterizing the mechanisms by which this change in expression is controlled. 13 There is no doubt that this enzyme has a vital physiological role as it is normally responsible for inactivating intracellular GCs in typical mineralocorticoid target tissues; however, recent findings in the literature coupled with the unique role that GCs play in skin cancer development and progression suggest that this enzyme may also play a substantial role in the multifactorial process of NMSC transformation.
In this study, we sought to characterize 11βHSD2 in in vitro mouse models of NMSC and to investigate whether it plays a role in transformation. We utilized 11βHSD2 siRNA and pharmacological 11βHSD2 inhibitor, Glycyrrhetinic acid (GA) to knock down 11βHSD2 and study the effect this would have on TPA-induced transformation of well-established mouse models of NMSC. We also validated our 11βHSD2 characterization results from our in vitro mouse studies using a human in vitro model of NMSC to ascertain whether the same results could be achieved in a human model for clinical relevance. Finally, we performed an in vivo, two-stage mouse carcinogenesis study over the course of 30 weeks to study the effect of 11βHSD2 inhibition by GA on DMBA/TPA-induced tumorigenesis. Our in vitro results in both mouse and human NMSC cell models show an upregulation of 11βHSD2 in cancer cells versus normal skin cells. Moreover, upon addition of a tumor promoter to induce transformation, we see an upregulation of 11βHSD2 in preneoplastic mouse keratinocytes. Corresponding with these results, our in vivo mouse studies also suggest a critical role for this enzyme in tumorigenesis as inhibition of 11βHSD2 with GA considerably delayed tumor onset and significantly decreased tumor incidence.
Given the ability of GCs to alter signaling in key survival pathways and the fact that similar to many chemotherapeutic agents, skin cancer patients often develop resistance to GC therapy, an investigation into the role of 11βHSD2 in skin cancer development/progression and GC resistance is of significant relevance. As stated before, characterization of 11βHSD2 in NMSC has never been evaluated elsewhere, therefore these findings elucidate an important role for this enzyme in NMSC and may identify 11βHSD2 as a potential target for prevention and or therapy of NMSC.
| Reagents
DMBA, TPA, and GA were obtained from Sigma-Aldrich (St. Louis, MO). Stock solutions of GA (up to 20 mM) and TPA (10 mg/mL) were prepared in ethanol for in vitro studies and then diluted down for experiments. For in vivo studies, DMBA and TPA were prepared according to previously established protocol by Abel et al. 18 For Western blotting analyses, primary antibodies used were for GR (Santa Cruz Biotechnology, Dallas, TX), 11βHSD1 (Santa Cruz Biotechnology), 11βHSD2 (Abcam, Cambridge, MA), and β-actin (Abcam). Secondary antibodies for mouse and rabbit were both from Biorad (Biorad, Hercules, CA). Silencer select siRNA for 3 different regions of mouse 11βHSD2 were obtained; S67837, S67838, and S67839 (Ambion, Foster City, CA).
| Cell culture
To investigate the importance of 11βHSDs in transformation using in vitro skin cancer models, we employed the use of two wellestablished cell models of skin cancer; the JB6 mouse epidermal cell lines generously provided to us by the laboratory of Nancy Colburn, and a second model consisting of 3PC, MT1/2, and Ca3/7 cells which was generated in our own lab, the laboratory of Thomas J.
Slaga. The JB6 model consists of clonal genetic variants that are promotion-sensitive (P+), promotion-resistant (P−) or transformed (Tx). The JB6 model is a widely used inducible model to study transformation, promotion, and progression at the molecular level.
This model system of cell lines originated from untreated primary BALB/c mouse epidermal cell cultures that gave rise at a very low MANCHA-RAMIREZ ET AL. | 103 frequency to immortalized cell lines. 19 Then immortalized JB6 cells underwent further change to stably acquire sensitivity to induction of anchorage independence and tumorigenicity by TPA and other tumor promoters. 20 Nonselective cloning soon after observation of this change lead to the development of clonal lines that were either sensitive (P+) or resistant (P−) to tumor-promoter-induced neoplastic transformation. [19] [20] [21] were plated into 100 mm dishes and allowed to grow for 48 h after which they were lysed and collected for whole cell Western blot analysis.
| Anchorage independence assay of RT101 cells transiently transfected with si_HSD2
Immediately following transient knockdown of 11βHSD2, a 10 4 aliquot of cells were taken and directly added to a 0.33% agar medium solution with 10%FBS. The cell suspension/agar medium solution was poured as a top layer to previously prepared bottom layers of 0.5% agarose/10%FBS solution in a 6-well plate. Cells were culture at 37°C, 5% CO 2 for 10-14 days. Where treatments were performed in soft agar, drug treatments were added to top layer prior to pouring, and final concentration was adjusted accordingly; acetone was used as a vehicle. After 10-14 days, colonies were stained using crystal violet and quantified.
| Animal model and experimental conditions
The ability of GA to inhibit tumorigenesis was examined by utilizing the two-stage skin carcinogenesis model. Healthy female FVB mice aged 6-7 weeks were obtained from Jackson Laboratories, Bar Harbor, ME.
Upon arrival, animals were randomly segregated into eight groups:
Control, DMBA/TPA, GA (low), GA (mid), GA (high), DMBA/TPA/ GA(L), DMBA/TPA/GA(M), and DMBA/TPA/GA(H) ( Figure 1 ). Each group contained 28 animals total, with eight animals whose endpoint would be the short-term date, and 20 remaining animals whose endpoint would be at the end of the study (long term). Animals were housed in a controlled atmosphere, under hygienic conditions, with 12-h light/dark cycles, and were provided standard animal feed. Prior to the start of the experiment, the animals were given an acclimation period of 1 week. To expose the skin of the mice for topical treatments, an approximate 2 × 3 cm portion of the dorsal region of each mouse was shaved with surgical clippers 2 days prior to the start of any topical application of compounds. 
| Statistical analyses
For in vitro studies, data are expressed as mean ± SD. Students t-test or ANOVA were used to calculate P values, and statistical significance was established at P < 0.05. All statistical analyses were performed using Graphpad Prism. For in vivo studies, data was collected for both tumor incidence and total number of lesions.
Tumor incidence was defined as the number of animals showing carcinogenic response/total number of animals in the group. For comparisons between two groups, a Student's t-test was used, and when comparing multiple groups, ANOVA was used. For analyzing differences between groups over time, the fisher's exact test was used to determine significance among two groups at a specific time point. For all analyses, P < 0.05 was accepted for statistical significance. All statistical analyses were performed using GraphPad Prism (GraphPad, CA).
| RESULTS

| 11βHSD2 expression is upregulated in mouse and human in vitro models of NMSC when compared to normal tissue counterparts
As upregulation of 11βHSD2 in tumors and cancer cells versus their normal counterparts has been shown in several different cancer types,
Detailed animal treatment schedule to study the effect of Glycyrrhetinic acid on DMBA/TPA induced skin tumorigenesis. All treatments described were administered topically in acetone to the shaved dorsal area of mice. Group 1, the control group mice were treated with 200 μL acetone twice weekly throughout the treatment period, and at each instance where TPA was administered. In the DMBA/TPA group, DMBA administration was performed only once at week zero to groups 2, 6, 7, and 8 in a dose of 50 μg/200 μL. In each group where DMBA was administered, TPA was also given twice weekly at a dose of 2 μg/200 μL for the duration of the study. GA control, groups 3, 4, and 5, each received their respective dose of GA (at 0.25 μmol, 0.5 μmol, and 1 μmol concentrations of GA) twice weekly. For our experimental groups, 6, 7, and 8, GA was administered at the respective dose (0.25 μmol, 0.5 μmol, and 1 μmol) 30 min prior to TPA treatment, twice weekly for entire length of the study but has never been evaluated in NMSC, we characterized the protein expression level of this enzyme in two well-established mouse skin cancer models in order to determine whether 11βHSD2 was upregulated in skin cancer as it has been shown to be in other cancer types in the literature. To investigate the expression of 11βHSD2 in NMSC, we utilized the JB6 mouse epidermal keratinocyte model consisting of P+ and RT101 cells, and a second mouse NMSC model consisting of 3PC, MT1/2, and Ca3/7 cells. Our results showed that in transformed RT101 cells, basal 11βHSD2 protein levels were significantly elevated when compared with levels in untreated, preneoplastic JB6 P+ cells (Figure 2A ). Further, 11βHSD2 protein expression significantly increased in JB6 P+ cells after treatment with tumor promoter, TPA, when compared to acetone, the vehicle control ( Figure 2A ). When our second mouse NMSC model was Figure 2B ). These results parallel those which we obtained in our mouse in vitro studies and align with similar findings in other cancer types in the literature.
| 11βHSD2 transient knockdown in soft agar significantly reduces TPA-induced colony formation of JB6 P+ cells and transformed RT101 cells
As transformed epidermal keratinocytes, RT101 cells will readily form colonies in soft agar. Thus, we sought to determine the role of 11βHSD2 in tumorigenesis by investigating whether 11βHSD2 knockdown in a transformed cell line could prevent or diminish colony formation in soft agar. As colony formation in the soft agar assay is the most efficacious correlate to tumorigenesis in vitro, determining the effect of 11βHSD2 inhibition utilizing this assay would give great insight into future in vivo tumorigenesis studies. When P+ cells were treated with TPA and 11βHSD2 was transiently knocked down, we saw a significant reduction in colony formation as compared to the scramble ( Figure 2C ). Further, we found that transient knockdown of 11βHSD2 in transformed RT101 cells resulted in significantly diminished colony formation over a 10-day period when compared to the non-specific scramble ( Figure 2C ). Using a pool of siRNAs for 11βHSD2 and 3 distinctly individual siRNA for 11βHSD2, we observed similar results, whereby transient knockdown of 11βHSD2 resulted in significantly reduced RT101 colony formation in soft agar with both the pooled siRNA and also with 2 individual siRNA specific for 11βHSD2 ( Figure 2C ). Figure 4A ). Compared to the DMBA/TPA-treated group, GA significantly reduced the tumor incidence ( Figure 4B ) and multiplicity of skin tumor formation ( Figure 4C ). Tumor incidence data over both phase I and phase II of our in vivo study (26 weeks) show significant decreases in tumor incidence in TPA/GA(L) and TPA/GA(H) group for weeks 6-16 when compared to TPA control. Although TPA/GA(L) did not reach significance, this dose was still able to reduce tumor incidence when compared to the TPA alone group. Here, tumor incidence is defined as the number of animals presenting with at least one tumor. Moreover, it substantially delayed the tumor latency period by 2 weeks in the lowest GA dose ( Figure 4D ). Treatment with GA in all three experimental groups (low, medium, and high [GA]) resulted in an increase in percent tumor-free mice, with TPA/GA(L) and TPA/GA(H) showing significant increases when compared to TPA control.
Even as late as 16 weeks, there is approximately a 40% difference in tumor-free mice in the TPA/GA(L) group when compared to the TPA control group which dropped below 50% tumor-free mice by 10 weeks.
| GA significantly decreases squamous cell carcinoma incidence when compared to DMBA/TPA alone, but does not have the same effect on papilloma incidence
While GA treatment resulted in significant reduction of tumor incidence and an increase in tumor latency, it was also important to qualify whether this treatment specifically targeted the development of a particular type of lesion. Therefore, H&E stained tissues were analyzed by a pathologist to determine the specific lesion incidence in each group. As malignant conversion from papilloma to SCC is a critical step in the later stage of the DMBA/TPA two-stage carcinogenesis method, results from this analysis offer further insight into the specific effect of GA on tumorigenesis. Our results show that GA-mediated 11βHSD2 inhibition significantly decreased percent SCC incidence in the DMBA/TPA/GA(L) and DMBA/TPA/GA(H) groups by approximately 40% ( Figure 4E) . Although there was a decrease in papilloma incidence in the DMBA/TPA/GA(L) group as well, it did not reach significance. As significant differences between papilloma incidences across all groups were undetectable, but two groups showed a significant reduction in SCC as compared to DMBA/TPA control, it is possible that GA may have a stronger negative effect on conversion from papilloma to SCC rather than papillomagenesis.
2.6 | GA significantly inhibits TPA-induced 11βHSD2 expression in long-term mouse tumor tissue As the animal data shows a significant effect of GA-mediated 11βHSD2 inhibition on tumorigenesis in the DMBA/TPA model of skin carcinogenesis, our next question was whether inhibition of 11βHSD2 by GA played a part in the results we observed. Therefore, we performed Western blot analyses on tumor tissues isolated from mice at both short-term and long-term endpoints to characterize 11βHSD1 and 11βHSD2 in both phases of the study. Our results showed that in both the short-and long-term phases of the study, 11βHSD2 protein expression was significantly induced by treatment with TPA when compared to vehicle-treated animals ( Figure 5 ). This suggests a possible novel role for 11βHSD2 in the multifactorial process of carcinogenesis as many other studies have reported similar findings in other types of cancer. Moreover, an overall trend amongst the 11βHSDs in both short-and long-term phases was observed, wherein 11βHSD1 was higher in vehicle-treated tissue than in TPAtreated tissue, and conversely 11βHSD2 was higher in TPA-treated tissues and lower in vehicle-treated tissues ( Figure 5 ). These results suggest 11βHSD2 may play a role in tumorigenesis in NMSC, as a switch in 11βHSD1/11βHSD2 expression like the one we observed in our Western blot analyses has been shown in other cancer models.
Additionally, both short-and long-term studies showed a considerable reduction in TPA-induced 11βHSD2 protein expression in the TPA/GA (L) group when compared to the TPA control ( Figure 5) , with the effect in the short-term being the most dramatic. Taken together, these findings may suggest an important role for 11βHSD2 in NMSC, where it may be significantly induced by TPA-treatment to aid in NMSC development or progression.
| DISCUSSION
As GCs are known to play an essential role as regulators of cell proliferation and differentiation, modulating their activation in a tissue-specific manner could be extremely advantageous in terms of inhibiting the induction of certain cancers. 11βHSDs are key regulators of GC activation/inactivation whose function happens at the pre-receptor level, and therefore these enzymes could serve as potential therapeutic targets in for skin cancer. Recently, several studies have reported aberrant 11βHSD2 expression in cancer cells versus normal cell counterparts, suggested a role for 11βHSD2 in transformation, and the possibility that inhibition of this GCmodulating enzyme could serve as a novel therapeutic target. 13 For example, lung cancer studies have revealed that 11βHSD2 expression was increased in human lung cancers and experimental lung tumors. 22 When 11βHSD2 was inhibited, lung tumor growth and invasion were suppressed and this correlated with increased active glucocorticoid levels in tissues. 22 Other noteworthy findings occurred in colon cancer, wherein 11βHSD2 inhibition by both pharmacological inhibitor and gene silencing prevented adenoma formation, tumor growth, and metastasis in an animal model. 17 Relevant findings have also been elucidated in breast cancer as well, where 11βHSD2 was observed in 66% of the breast tumor samples evaluated. 12 Overexpression of 11βHSD2 in MCF-7 cells reversed the antiproliferative effects of GCs in these cells and increased overall cell growth. 23 These results suggest an increased expression of 11βHSD2 may have the ability to abrogate the antiproliferative action of GCs in certain tissues.
In these studies, we characterized 11βHSD2 in well-established in vitro and in vivo models of NMSC, which had never been previously evaluated. We also sought to determine if 11βHSD2 plays a role in the multifactorial process of NMSC transformation. We hypothesized that 11βHSD2 contributes to malignant transformation in NMSC. We observed greater expression of 11βHSD2 in transformed RT101 cells FIGURE 4 A, Chemopreventive effect of GA on DMBA/TPA-induced skin cancer in FVB mice. GA treatment significantly reduces average tumor weight in the short-term timeline when compared to DMBA/TPA control. Twice-weekly topical application of GA 30 min prior to TPAtreatment resulted in a significant decrease in average tumor weight in all three experimental DMBA/TPA/GA groups (low, medium, and high doses). B, Tumor incidence data over both phase I and phase II of our in vivo study (26 weeks) show significant decreases in tumor incidence in TPA/GA(L) and TPA/GA(H) group for weeks 6-16 when compared to TPA control. C, Average number of tumors per mouse over both phase I and phase II of our in vivo study (26 weeks) . All 3 groups elicited a significant reduction in average number of tumors/mouse when compared to the TPA alone group. D, Latency of tumors was increased in all experimental groups compared to TPA control by 2 weeks. Treatment with GA in all three experimental groups (low, medium, and high [GA]) resulted in an increase in percent tumor-free mice, with TPA/GA(L) and TPA/GA(H) showing significant increases when compared to TPA control. E, Incidence of SCC is significantly decreased by GA treatment; Histological analysis of tissue samples after undergoing 26 weeks of TPA-treatments reveals that treatment with GA significantly decreased the percent incidence of SCC in two out of three experimental groups (TPA/GA(L) and TPA/GA(H)). P < 0.05 were considered to be statistically significant (*) when compared to their normal counterparts, which correlates with the "switch" observed in the literature in other types of cancer whereby normal cells will begin to preferentially express 11βHSD2 as they undergo transformation. When JB6+ epidermal keratinocytes underwent transformation by the addition of tumor promoter, TPA, we observed a significant increase in 11βHSD2 expression. Further, we tested a second well-established in vitro mouse model of NMSC to determine if the upregulation of 11βHSD2 was prevalent in different types of mouse NMSC cells, and found 11βHSD2 was upregulated in both tumorigenic cell lines, MT1/2 and Ca3/7, but not in the nontumorigenic line, 3PC. These results suggest 11βHSD2 may play a role in transformation of NMSC, and may serve as a novel target for prevention. We then validated this elevated 11βHSD2 expression trend in a human in vitro skin cancer model and found that the same upregulation of 11βHSD2 evident in our mouse models was also present in human cells. After using mouse and human cell lines to show cancer where it had previously not been evaluated. As the anchorage independent colony formation assay is typically considered to be an in vitro indicator of tumorigenicity, these results suggest that when 11βHSD2 is inhibited in an animal model, we may be able to achieve minimized tumor size or diminished tumor formation. Therefore, we next sought to test this hypothesis in an in vivo mouse NMSC model.
We evaluated the effect of 11βHSD2 expression inhibition in a well-established in vivo model of NMSC using phytonutrient, GA as an inhibitor of the enzyme. We chose GA because phytonutrients are naturally derived compounds isolated from plants, which can modulate disease progression and have been widely studied for their efficacious use in cancer and other diseases. 24 Pentacyclic triterpenoids have been shown to be efficacious in inhibition of skin tumorigenesis, however, the role of 11βHSD2 as a target in this chemopreventive process has not been evaluated. In our in vivo studies, we observed a significant decrease in tumor incidence, a significant decrease in squamous cell carcinoma incidence, and an increase in tumor latency in the DMBA/TPA/GA experimental groups as compared to the DMBA/ TPA group. Histopathological evaluation of tissues showed that topical administration of GA did not have any adverse effects on the epidermis or mouse weight over 26 weeks. Histological analysis of the DMBA/ TPA group also show a characteristically thickened epidermis, that is, absent in GA control groups and diminished in DMBA/TPA/GA experimental groups. To investigate whether inhibition of 11βHSD2 played a role in the decrease in tumors exerted by GA treatment, we evaluated 11βHSD2 protein expression in tissues from both phase 1 (short-term) and phase 2 (long-term) animals. Our results show a significant induction of 11βHSD2 protein expression in in TPA-treated tissues when compared to vehicle-treated tissues from both short-and long-term phases. An overall trend amongst the 11βHSDs in both short-and long-term phases was observed, wherein 11βHSD1 was higher in vehicle-treated tissue than in TPA-treated tissue, and conversely 11βHSD2 was higher in TPA-treated tissues and lower in vehicle-treated tissues. These results correlate with the "switch" reported in the literature in other models which we mentioned earlier in the introduction. These findings further validate our earlier in vitro studies, where we observed a significant induction of 11βHSD2 protein expression upon TPA treatment, and saw the same inverse expression trend between 11βHSD1 and 11βHSD2. Finally, GA abrogated TPA-induced 11βHSD2 protein expression in both shortand long-term phases. Because GA-mediated 11βHSD2 inhibition resulted in significantly reduced tumor incidence as well as a delay of tumor onset in our in vivo work, this may elucidate a possible therapeutic approach for NMSC by modulating the 11βHSD2 enzyme in a tissue-specific manner. If GA is used to locally inhibit 11βHSD2 rather than systemic inhibition, adverse effects caused by 11βHSD2 inhibition should not be expected.
Given the rise of NMSC incidence, high rate of lesion recurrence, and serious tissue damage that can occur from lesion development, elucidating novel chemopreventive approaches to NMSC and a greater understanding of the mechanisms by which they occur are of critical importance. 2, [25] [26] [27] The goal of this study, was to investigate whether 11βHSDs, pre-receptor regulators of GC activation, played a role in NMSC development and/or progression; this was achieved by using pharmacological 11βHSD2 inhibitor, GA, in conjunction with tumor promoter, TPA, to determine if 11βHSD2 inhibition could significantly abrogate tumorigenesis. Major findings of this study are that 11βHSD2 expression is upregulated in TPA-treated in vitro and in vivo models of NMSC, and both genetic knockdown and pharmacological inhibition of 11βHSD2 result in significantly reduced soft agar colony formation and tumorigenesis in cell and animal models respectively. Results of this study are significant because the specific role of 11βHSDs in NMSC have not been well-studied, and many others have suggested 11βHSD2 may be a pro-proliferative force because of its ability to inactivate glucocorticoids in a tissue-specific manner. [12] [13] [14] 23 The role of 11βHSD2 in tumorigenesis has already been elucidated in colorectal cancer, and its inhibition has suppressed colon carcinogenesis in both mouse and human models. 17, 28 As GCs are well-known inhibitors of cell proliferation and inducers of cell differentiation via GRs, prereceptor regulation of the availability of active GCs to the receptor is vital for tightly maintaining the proper function of GCs in specific situations. It is highly disadvantageous for the tumor environment to have the capability to increase 11βHSD2 expression in a tissuespecific manner to achieve a decrease in the functionality of GCs; such an environment would result in GC inactivation, reduced antiinflammatory signals, and a setting that favors tumorigenesis. Further investigation into understanding the mechanistic players involved in GA-mediated 11βHSD2 inhibition is certainly warranted to provide a more thorough understanding of the impact of these findings. In conclusion, this work has characterized the 11βHSD enzymes in wellestablished human and mouse in vitro and mouse in vivo models of skin cancer, shown a significant role for 11βHSD2 in transformation of NMSC in mouse in vitro models, and elucidated GA-mediated 11βHSD2 inhibition to be a potential chemopreventive target for prevention tumorigenesis in a well-studied mouse model of NMSC.
